Association between inflammatory bowel disease and bullous pemphigoid: a population-based case-control study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 07 2020
29 07 2020
Historique:
received:
12
03
2020
accepted:
13
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
18
12
2020
Statut:
epublish
Résumé
The coexistence of inflammatory bowel disease (IBD) and bullous pemphigoid (BP) has been reported. No large-scale study to date has explored the relationship between these diseases. This population-based case-control study examined the association between IBD and BP by using a nationwide database. A total of 5,263 BP patients and 21,052 age- and gender-, hospital visit number-matched controls were identified in the National Health Insurance Research Database of Taiwan (1997-2013). Demographic characteristics and comorbidities including IBD were compared. Logistic regression was conducted to examine the predicting factors for BP. The mean age at diagnosis was 74.88 years and 54.3% of subjects were male. BP patients tended to have more cardiovascular risk factors, autoimmune and neurologic comorbidities, and hematologic cancers than matched controls. There were 20 cases of IBD (0.38%), mostly ulcerative colitis (N = 17, 0.32%) among BP patients, compared to 33 IBD cases (0.16%) among controls (p < 0.001). Ulcerative colitis was found to be significantly associated with BP [adjusted odds ratio (OR) 3.60, 95% confidence interval (CI) 1.91-6.77, p < 0.001] on multivariate analysis. Treatment for IBD was not associated with BP development. Information about diet, lifestyle, alcohol consumption, and smoking habit was not available. We concluded that UC is independently associated with BP.
Identifiants
pubmed: 32728039
doi: 10.1038/s41598-020-69475-0
pii: 10.1038/s41598-020-69475-0
pmc: PMC7391771
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12727Références
Genovese, G. et al. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front. Immunol. 10, 1506. https://doi.org/10.3389/fimmu.2019.01506 (2019).
doi: 10.3389/fimmu.2019.01506
pubmed: 31312206
pmcid: 6614376
Kridin, K. & Ludwig, R. J. The growing incidence of bullous pemphigoid: overview and potential explanations. Front. Med. 5, 220. https://doi.org/10.3389/fmed.2018.00220 (2018).
doi: 10.3389/fmed.2018.00220
Chen, Y. J. et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br. J. Dermatol. 165, 593–599 (2011).
doi: 10.1111/j.1365-2133.2011.10386.x
Bech, R., Kibsgaard, L. & Vestergaard, C. Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing literature. Front. Med. 5, 238. https://doi.org/10.3389/fmed.2018.00238 (2018).
doi: 10.3389/fmed.2018.00238
Kibsgaard, L. et al. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br. J. Dermatol. 176, 1486–1491 (2017).
doi: 10.1111/bjd.15405
Kibsgaard, L., Bay, B., Deleuran, M. & Vestergaard, C. A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. Acta. Derm. Venereol. 95, 307–311 (2015).
doi: 10.2340/00015555-1925
Ren, Z. et al. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA. Br. J. Dermatol. 176, 87–99 (2017).
doi: 10.1111/bjd.14821
Horie, M., Yoshioka, N. & Takebayashi, H. BPAG1 in muscles: Structure and function in skeletal, cardiac and smooth muscle. Semin. Cell. Dev. Biol. 69, 26–33 (2017).
doi: 10.1016/j.semcdb.2017.07.016
Kedia, S., Limdi, J. K. & Ahuja, V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest. Res. 16, 194–208 (2018).
doi: 10.5217/ir.2018.16.2.194
Wilson, J. C., Furlano, R. I., Jick, S. S. & Meier, C. R. Inflammatory bowel disease and the risk of autoimmune diseases. J. Crohn’s. Colitis. 10, 186–193 (2016).
doi: 10.1093/ecco-jcc/jjv193
Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54 (2012).
doi: 10.1053/j.gastro.2011.10.001
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018).
doi: 10.1016/S0140-6736(17)32448-0
Yen, H. H. et al. Epidermiological trend of inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population based study. Intest. Res. 17, 54–62 (2019).
doi: 10.5217/ir.2018.00096
Matsuoka, K. & Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 37, 47–55 (2015).
doi: 10.1007/s00281-014-0454-4
Shipman, A. R., Reddy, H. & Wojnarowska, F. Association between the subepidermal autoimmune blistering diseases linear IgA disease and the pemphigoid group and inflammatory bowel disease: two case reports and literature review. Clin. Exp. Dermatol. 37, 461–468 (2012).
doi: 10.1111/j.1365-2230.2012.04383.x
Hoffmann, S., Berneburg, M. & Schreml, S. Bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis. Case. Rep. Dermatol. 10, 145–148 (2018).
doi: 10.1159/000489163
Selby, L., De Castro, F. & De Villiers, W. J. The association of bullous pemphigoid and ulcerative colitis. Dig. Dis. Sci. 49, 1768–1770 (2004).
doi: 10.1007/s10620-004-9567-2
Vaccaro, M., D’Amico, D., Borgia, F., Guarneri, F. & Cannavo, S. Bullous pemphigoid following use of sulphasalazine for ulcerative colitis: drug-induced eruption or true association?. Dermatology 203, 194–195 (2001).
doi: 10.1159/000051745
Harrison, P. V. et al. Bullous pemphigoid and ulcerative colitis: a report of two cases and description of immunoblot findings. Br. J. Dermatol. 134, 599–600 (1996).
doi: 10.1111/j.1365-2133.1996.tb16257.x
Barth, J. H. et al. Pemphigoid and ulcerative colitis. J. Am. Acad. Dermatol. 19(2 Pt 1), 303–308 (1998).
Ahmed, A. R., Kaplan, R. P., Hardy, D., Feldman, E. & Pitt, H. Bullous pemphigoid and ulcerative colitis. Int. J. Dermatol. 21, 594–598 (1982).
doi: 10.1111/j.1365-4362.1982.tb02042.x
Narla, S. & Silverberg, J. I. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. J. Am. Acad. Dermatol. 82, 586–595 (2020).
doi: 10.1016/j.jaad.2019.07.029
Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H. & Lai, M. L. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug. saf. 20, 236–242 (2011).
doi: 10.1002/pds.2087
Hsieh, C. Y., Chen, C. H., Li, C. Y. & Lai, M. L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J. Formos. Med. Assoc. 114, 254–259 (2015).
doi: 10.1016/j.jfma.2013.09.009
Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C. & Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J. Formos. Med. Assoc. 104, 157–163 (2005).
pubmed: 15818428
Wu, C. Y. et al. Association between nucleoside analogs and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308, 1906–1914 (2012).
doi: 10.1001/2012.jama.11975
Wu, C. Y. et al. Risk of inflammatory bowel disease in patients with rosacea: results from a nationwide cohort study in Taiwan. J. Am. Acad. Dermatol. 76, 911–917 (2017).
doi: 10.1016/j.jaad.2016.11.065
Lin, L. Y., Warren-Gash, C., Smeeth, L. & Chen, P. C. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol. Health. 40, e2018062 (2018).
doi: 10.4178/epih.e2018062
Aho, S. & Uitto, J. 180-kD bullous pemphigoid antigen/type XVII collagen: tissue-specific expression and molecular interactions with keratin 18. J. Cell. Biochem. 72, 356–367 (1999).
doi: 10.1002/(SICI)1097-4644(19990301)72:3<356::AID-JCB5>3.0.CO;2-M
Leung, C. L., Zheng, M., Prater, S. M. & Liem, R. K. The BPAG1 locus: Alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J. Cell. Biol. 154, 691–697 (2001).
doi: 10.1083/jcb.200012098
Moschen, A. R., Tilg, H. & Raine, T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 16, 185–196 (2019).
doi: 10.1038/s41575-018-0084-8
Zuo, T. & Ng, S. C. The Gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 9, 2247. https://doi.org/10.3389/fmicb.2018.02247 (2018).
doi: 10.3389/fmicb.2018.02247
pubmed: 30319571
pmcid: 6167487
Dragasevic, S. et al. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: gene expression profiling study. Clin. Immunol. 197, 86–95 (2018).
doi: 10.1016/j.clim.2018.09.001
Alinaghi, F. et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease: a systematic review and meta-analysis. J. Crohn’s. Colitis. 14, 351–360 (2020).
doi: 10.1093/ecco-jcc/jjz152
Arakawa, M. et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp. Dermatol. 20, 1022–1024 (2011).
doi: 10.1111/j.1600-0625.2011.01378.x
Chakievska, L. et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J. Autoimmun. 96, 104–112 (2019).
doi: 10.1016/j.jaut.2018.09.003
Zebrowska, A., et al. IL-17 expression in dermatitis herpetiformis and bullous pemphigoid. Mediators. Inflamm. 2013, 967987; 10.1155/2013/967987 (2013).
Plee, J., et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 5, 18001; 10.1038/srep18001 (2015).
Fu, Y., Lee, C. H. & Chi, C. C. Association of psoriasis with inflammatory bowel disease: a systemic review and meta-analysis. JAMA. Dermatol. 154, 1417–1423 (2018).
doi: 10.1001/jamadermatol.2018.3631
Chen, Y. J. et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br. J. Dermaol. 165, 593–599 (2011).
doi: 10.1111/j.1365-2133.2011.10386.x
Stavropoulos, P. G., Soura, E. & Antoniou, C. Drug-induced pemphigoid: a review of the literature. J. Eur. Acad. Dermatol. Venereol. 28, 1133–1140 (2014).
doi: 10.1111/jdv.12366
Ferris, L. K., Jukic, D., English, J. C. 3rd. & Zirwas, M. J. Drug-induced bullous pemphigoid caused by a generic Canadian medication obtained over the internet. Arch. Dermatol. 141, 1474–1476 (2005).
doi: 10.1001/archderm.141.11.1474-b
Kridin, K., Comaneshter, D. & Cohen, A. D. Short article: Crohn’s disease and pemphigus: is there an association? A population-based study. Eur. J. Gastroenterol. Hepatol. 30, 727–729 (2018).
doi: 10.1097/MEG.0000000000001140